The role of miR-29 isoforms in malignant hematopoiesis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150427" target="_blank" >RIV/61989592:15110/14:33150427 - isvavai.cz</a>
Result on the web
<a href="http://biomed.papers.upol.cz/pdfs/bio/2014/04/01.pdf" target="_blank" >http://biomed.papers.upol.cz/pdfs/bio/2014/04/01.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2014.029" target="_blank" >10.5507/bp.2014.029</a>

Result language
angličtina
Original language name
The role of miR-29 isoforms in malignant hematopoiesis
Original language description
Aims: MicroRNAs of the miR-29 isoforms were one of the first microRNAs identified as possible therapeutic agents in malignant hematopoiesis. The aim of our review is to summarize the current state of the knowledge on miR-29 isoforms. Methods: We performed literature searches involving miR-29 isoforms and their relationship to individual hematological malignancies, namely acute myeloid leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloid leukemia (CML). We also searched for subgroupsof hematological malignancies, e.g. multiple myeloma, that are regarded as members of the four general groups of leukemias. Results: A number of genes appear to be regulated by miR-29 isoforms in various physiological and pathological situations. In ourview regulation of Tcl-1, Mcl-1 and DNA methyltransferases is relevant in case of hematological malignancies, hence these are the focus of this review. miR-29 isoforms also function during normal T-cell and B-cell evolution. Conclusion: M
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
CE - Biochemistry
OECD FORD branch
—

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)